These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34668464)

  • 1. Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand.
    Carlton LH; Chen T; Whitcombe AL; McGregor R; Scheurich G; Sheen CR; Dickson JM; Bullen C; Chiang A; Exeter DJ; Paynter J; Baker MG; Charlewood R; Moreland NJ
    Epidemiol Infect; 2021 Jul; 149():e173. PubMed ID: 34668464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.
    Tuite AR; Fisman D; Abe KT; Rathod B; Pasculescu A; Colwill K; Gingras AC; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2022 Feb; 10(1):e0256321. PubMed ID: 35196819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation.
    Martinez-Acuña N; Avalos-Nolazco DM; Rodriguez-Rodriguez DR; Martinez-Liu CG; Galan-Huerta KA; Padilla-Rivas GR; Ramos-Jimenez J; Ayala-de-la-Cruz S; Cienfuegos-Pecina E; Diaz-Chuc EA; Cazares-Tamez R; Flores-Arechiga A; Perez-Chavez F; Arellanos-Soto D; Lozano-Sepulveda SA; Garza-Gonzalez E; Treviño-Garza C; Montes-de-Oca-Luna R; Lee-Gonzalez AB; de-la-O-Cavazos ME; Rivas-Estilla AM
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34202849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.
    Dodd RY; Spencer BR; Xu M; Foster GA; Saá P; Brodsky JP; Stramer SL
    Transfus Med Rev; 2021 Jul; 35(3):1-7. PubMed ID: 34373145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021.
    Kao S-YZ; Nycz E; Benoit TJ; Clarke KEN; Jones JM
    Microbiol Spectr; 2024 Aug; 12(8):e0012324. PubMed ID: 38869287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
    Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
    mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression and Predictors of SARS-CoV-2 Antibody Seroreactivity In US Blood Donors.
    Vassallo RR; Dumont LJ; Bravo MD; Hazegh K; Kamel H
    Transfus Med Rev; 2021 Jul; 35(3):8-15. PubMed ID: 34376289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The seroprevalence of SARS-CoV-2 in a rural southwest community.
    Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
    J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
    Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure.
    Hunter BR; Dbeibo L; Weaver CS; Beeler C; Saysana M; Zimmerman MK; Weaver L
    Infect Control Hosp Epidemiol; 2020 Dec; 41(12):1441-1442. PubMed ID: 32741406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned.
    Poljak M; Oštrbenk Valenčak A; Štrumbelj E; Maver Vodičar P; Vehovar V; Resman Rus K; Korva M; Knap N; Seme K; Petrovec M; Zupan B; Demšar J; Kurdija S; Avšič Županc T
    Clin Microbiol Infect; 2021 Jul; 27(7):1039.e1-1039.e7. PubMed ID: 33838303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study.
    Lewin A; Therrien R; De Serres G; Grégoire Y; Perreault J; Drouin M; Fournier MJ; Tremblay T; Beaudoin J; Beaudoin-Bussières G; Prévost J; Gendron-Lepage G; Finzi A; Bernier F; Bazin R; Germain M; Delage G
    Can J Public Health; 2021 Aug; 112(4):576-586. PubMed ID: 33999398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India.
    Selvaraju S; Kumar MS; Thangaraj JWV; Bhatnagar T; Saravanakumar V; Kumar CPG; Sekar K; Ilayaperumal E; Sabarinathan R; Jagadeesan M; Hemalatha MS; Murhekar MV;
    Emerg Infect Dis; 2021 Feb; 27(2):586-589. PubMed ID: 33496222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.
    Yoshiyama T; Saito Y; Masuda K; Nakanishi Y; Kido Y; Uchimura K; Mitarai S; Suzuki T; Nakagama Y; Kubota H; Satomi M; Uchikoba S; Ohnishi M; Wakita T; Kato S; Kato K
    Emerg Infect Dis; 2021 Feb; 27(2):628-631. PubMed ID: 33496235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic.
    Sughayer MA; Mansour A; Al Nuirat A; Souan L; Ghanem M; Siag M
    Int J Infect Dis; 2021 Jun; 107():116-120. PubMed ID: 33892190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.